Troutman Pepper Locke Advises Ocugen in License Agreement With Kwangdong

PHILADELPHIA – Troutman Pepper Locke advised Ocugen, Inc. (Ocugen), a pioneering biotechnology leader in gene therapies for blindness diseases, in the execution of a licensing agreement with Kwangdong Pharmaceutical, Co., Ltd. (Kwangdong), one of the leading pharmaceutical companies in Korea, for the exclusive Korean rights to OCU400 — Ocugen’s novel modifier gene therapy for retinitis pigmentosa. For more information, see the press release.

There are an estimated 7,000 individuals in the Republic of Korea with retinitis pigmentosa, which represents approximately 7% of the U.S. market. OCU400 provides the opportunity for Kwangdong to help thousands of patients facing vision loss. Upon regulatory approval of OCU400 in Korea, Kwangdong will be positioned to become a leader in the field of ophthalmic gene therapy in Korea.

The Troutman Pepper Locke team that advised Ocugen included Debbie Spranger, Elizabeth-Ann Weeks, Mindy Rudolph, Emily Makar, Joan Arnold, Peter Jeydel, Judy O’Grady, and Barbara Sicalides.

Troutman Pepper Locke’s leading Health Care and Life Sciences Practice encompasses the entire spectrum of health care and life sciences companies. The team collaborates across disciplines to solve complex legal challenges confronting clients, offering a full suite of corporate, intellectual property, regulatory, and litigation services. Few law firms have a comparable health care and life sciences practice, and Troutman Pepper Locke draws on its deep industry knowledge to provide the precise, holistic advice and guidance clients need throughout their business cycles.

Troutman Pepper Locke

Troutman Pepper Locke helps clients solve complex legal challenges and achieve their business goals in an ever-changing global economy. With more than 1,600 attorneys in 30+ offices, the firm serves clients in all major industry sectors, with particular depth in energy, financial services, health care and life sciences, insurance and reinsurance, private equity, and real estate. Learn more at troutman.com.